Biotech · Private company
Kadmon Corporation, LLC
Track this companyFree. Adds Kadmon Corporation, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials140 recruiting or active
Pipeline programs16From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline16
- ErlotinibPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- KD019Phase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- BelumosudilPhase 2 · Psoriasis VulgarisClinicalTrials.gov · fetched Nov 12, 2026
- BelumosudilPhase 2 · Chronic Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- BelumosudilPhase 2 · Idiopathic Pulmonary FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- BSCPhase 2 · Idiopathic Pulmonary FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- KD025Phase 2 · Psoriasis VulgarisClinicalTrials.gov · fetched Nov 12, 2026
- tesevatinibPhase 2 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)ClinicalTrials.gov · fetched Nov 12, 2026
- TesevatinibPhase 2 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
- TesevatinibPhase 2 · HER-2 Positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- TesevatinibPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- TrastuzumabPhase 2 · HER-2 Positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- XL647Phase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- XL647Phase 2 · Non-small-cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- TesevatinibPhase 1 · Polycystic Kidney, Autosomal RecessiveClinicalTrials.gov · fetched Nov 12, 2026
- XL647Phase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials14
- A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)PHASE1 · COMPLETED · started Aug 24, 2017ClinicalTrials.gov NCT03096080 · fetched Nov 12, 2026
- A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque PsoriasisPHASE2 · COMPLETED · started Sep 14, 2016ClinicalTrials.gov NCT02852967 · fetched Nov 12, 2026
- Study of Tesevatinib Monotherapy in Patients With Recurrent GlioblastomaPHASE2 · COMPLETED · started Jun 1, 2016ClinicalTrials.gov NCT02844439 · fetched Nov 12, 2026
- A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary FibrosisPHASE2 · COMPLETED · started May 26, 2016ClinicalTrials.gov NCT02688647 · fetched Nov 12, 2026
- Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101PHASE2 · TERMINATED · started Dec 25, 2015ClinicalTrials.gov NCT02616055 · fetched Nov 12, 2026
- Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal MetastasesPHASE2 · COMPLETED · started Nov 1, 2015ClinicalTrials.gov NCT02616393 · fetched Nov 12, 2026
- Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line TherapyPHASE2 · COMPLETED · started Dec 1, 2014ClinicalTrials.gov NCT02317627 · fetched Nov 12, 2026
- Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast CancerPHASE1_PHASE2 · TERMINATED · started May 1, 2014ClinicalTrials.gov NCT02154529 · fetched Nov 12, 2026
- A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis VulgarisPHASE2 · COMPLETED · started Apr 1, 2014ClinicalTrials.gov NCT02106195 · fetched Nov 12, 2026
- KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line ChemotherapyPHASE3 · TERMINATED · started Dec 14, 2011ClinicalTrials.gov NCT01487174 · fetched Nov 12, 2026
- Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or ErlotinibPHASE2 · COMPLETED · started May 1, 2007ClinicalTrials.gov NCT00522145 · fetched Nov 12, 2026
- Study of XL647 Administered Orally Daily to Patients With Solid TumorsPHASE1 · COMPLETED · started Jul 1, 2006ClinicalTrials.gov NCT00336765 · fetched Nov 12, 2026
- Study of XL647 in Subjects With Non-Small-Cell Lung CancerPHASE2 · COMPLETED · started Jul 1, 2006ClinicalTrials.gov NCT00364780 · fetched Nov 12, 2026
- Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid TumorsPHASE1 · COMPLETED · started Jun 1, 2004ClinicalTrials.gov NCT00086528 · fetched Nov 12, 2026